Drug intelligence / Profile preview

2,5-bis(4-(diethylamino)benzylidene)cyclopentanone

Development stage: Preclinical
Modality: Small Molecules

Overview

BDBC (2,5-bis(4-(diethylamino)benzylidene)cyclopentanone) is a chemical compound utilized as a key component in carrier-free core-shell nanodrugs, specifically BCNPs, designed for synergistic two-photon photodynamic therapy (PDT) in the treatment of cervical cancer. When co-assembled with curcumin, BDBC significantly contributes to a high singlet oxygen yield and demonstrates enhanced efficacy in inhibiting the proliferation of HeLa cells under 450/808 nm irradiation. This compound's role is crucial in the synergistic therapeutic approach for cancer.

Targets

^1O2 (Singlet oxygen)

Beyond the preview

Go deeper on 2,5-bis(4-(diethylamino)benzylidene)cyclopentanone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,5-bis(4-(diethylamino)benzylidene)cyclopentanone.

Explore the full profile